Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SAN DIEGO, Feb. 08, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the close of a $5 million financing. This financing included both existing and new individual investors and provides SENTÉ with a sizable cash balance to fuel expansion and continued company growth.
“We are very pleased to continue seeing such strong investor interest in our company from leading experts in the healthcare and aesthetic field,” said Kleanthis G. Xanthopoulos, Ph.D., SENTÉ Co-Founder and Board Member. “Our investors share our vision in creating unique science based dermatological products that will have profound impacts on the skin, and we very much look forward to continued growth in this endeavor."
The Company, which realized top line year over year growth of 266%, will use this financing to increase its domestic sales force, support the launch of new and innovative products, pursue international expansion and invest behind meaningful new technologies.
“We are excited about the significant progress SENTÉ made in 2015 and we are equally pleased with the continued financial support of our investors,” said Faheem Hasnain, Chairman of the Board of SENTÉ. “We look forward to an exciting year in 2016 with continued strong revenue growth.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through our exclusive network of physicians and medically supervised spas.
Financial Contact: Michael Brower Chief Financial Officer [email protected] p: 760.478.3603 Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
